Nanjing Hicin Pharmaceutical Co., Ltd.

300584

CNE100002F44

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 12/05/2024 BST			5-day change	1st Jan Change
18.54 ^CNY	+0.27%		+0.82%	-20.36%

04-25	Nanjing Hicin Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year 2023	CI
04-24	Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Nanjing Hicin Pharmaceutical Co., Ltd. Announces Management Changes

July 18, 2022 at 08:32 pm

Nanjing Hicin Pharmaceutical Co., Ltd. at the extraordinary general meeting held on July 15, 2022 approved Cao Xichen as non-independent directors and Zhu Liye as non-employee supervisors.

Latest news about Nanjing Hicin Pharmaceutical Co., Ltd.

Nanjing Hicin Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year 2023	04-24	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-24	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	26/10/23	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	22/08/23	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	24/04/23	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	24/04/23	CI
Nanjing Hicin Pharmaceutical Co., Ltd. cancelled the transaction announced on June 10, 2022	12/02/23	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	25/10/22	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	25/08/22	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Management Changes	18/07/22	CI
Nanjing Hicin Pharmaceutical Co., Ltd. announced that it expects to receive CNY 400 million in funding	09/06/22	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Cash Dividend on A Shares for the Year 2021, Payable on May 25, 2022	19/05/22	CI
Nanjing Hicin Pharmaceutical Approves Profit Distribution for 2021	17/05/22	CI
Nanjing Hicin Pharmaceutical Proposes Profit Distribution for 2021	22/04/22	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	21/04/22	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	25/10/21	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	03/08/21	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2020, Payable on May 13, 2021	30/04/21	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Profit Distribution Proposal for 2020	08/04/21	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Earnings Results for the First Quarter Ended March 31, 2021	07/04/21	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	29/10/20	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	17/08/20	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces 2019 Final Distribution Plan to Be Implemented (A Shares), Payable on May 14, 2020	07/05/20	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Approves the Final Cash Dividend for the Year 2019	30/04/20	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2020	20/04/20	CI

Chart Nanjing Hicin Pharmaceutical Co., Ltd.

Duration

Period

Chart Nanjing Hicin Pharmaceutical Co., Ltd.

More charts

Nanjing Hicin Pharmaceutical Co Ltd is a pharmaceutical company engaged in research, development and production of chemical preparations, active pharmaceutical ingredients and intermediates. The Company's primary products are torsemide for injection, tigecycline for injection, cefoxitin sodium for injection, cefotiam for injection and omeprazole sodium for injection. The torsemide for injection is a loop diuretic. The tigecycline for injection is an intravenous administrated glycyrrhizin antibiotic for the treatment of complex skin and skin structure infections or complex intra-abdominal infections. The cefoxitin sodium for injection is a cephalosporin antibiotic used for the treatment of respiratory, urinary and gastrointestinal infections. Its products cover a range of therapeutic areas, including diuresis, cardiovascular, anti-infection, digestive system, immune regulation, hypoglycemic and orthopedics.

Sector

Pharmaceuticals

Calendar

15/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NANJING HICIN PHARMACEUTICAL CO., LTD.	-20.36%	307M
ELI LILLY AND COMPANY	+29.98%	684B
NOVO NORDISK A/S	+30.34%	568B
JOHNSON & JOHNSON	-3.52%	361B
MERCK & CO., INC.	+18.59%	329B
ABBVIE INC.	+4.07%	284B
ASTRAZENECA PLC	+16.21%	240B
NOVARTIS AG	+9.66%	208B
ROCHE HOLDING AG	-6.83%	200B
AMGEN INC.	+7.09%	166B

Other Pharmaceuticals